Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer
作者： Jiheum Paek , San-Hui Lee , Ga-Won Yim , Maria Lee , Young-Jae Kim
DOI: 10.1016/J.EJOGRB.2011.05.021
关键词:
摘要: Abstract Objective The purpose of this study was to evaluate the prognostic significance serum human epididymis protein 4 (HE4) level in patients with epithelial ovarian cancer. Study design A total 78 women diagnosed a pelvic mass and operated on our institute comprised cohort. Forty-five these were cancer treated debulking surgery, followed by taxane platinum-based chemotherapy as clinically indicated. Preoperatively obtained samples analyzed for levels HE4 CA125. Results elevated related advanced stage serous type median duration follow-up 35.1 months. In stage, progression-free survival (PFS) 20.1 months (95% CI, 15.7–24.6 months), whereas that normal 24.2 13.9–34.6 months) (p = 0.029). Independent predictors PFS EOC included (hazard ratio 2.24; 95% 1.14 6.84; p = 0.048). Conclusions Our results demonstrated an An is poor factor who surgery adjuvant chemotherapy. promising indicator progression well biomarker detection
elsevier.com
ajou.ac.kr参考文章(26)
Friedlander Ml, Prognostic factors in ovarian cancer. Seminars in Oncology. ,vol. 25, pp. 305- 314 ,(1998)
Alan B. Zonderman, Kathleen R. Cho, Patrice J. Morin, Colleen D. Hough, Donald R. Schwartz, Coordinately Up-Regulated Genes in Ovarian Cancer Cancer Research. ,vol. 61, pp. 3869- 3876 ,(2001)
Charles Drescher, John Raycraft, Martin McIntosh, Martha Hayden-Ledbetter, Nicole Urban, Michèl Schummer, Karl Erik Hellström, Jeffrey A Ledbetter, Ingegerd Hellström, The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma Cancer Research. ,vol. 63, pp. 3695- 3700 ,(2003)
Jacqueline M. Lafky, Vera J. Suman, Cecelia H. Boardman, Andre T. Baron, Nita J. Maihle, Swarna Balasubramaniam, Karl C. Podratz, Serum sErbB1 and Epidermal Growth Factor Levels As Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer Cancer Epidemiology, Biomarkers & Prevention. ,vol. 8, pp. 129- 137 ,(1999)
Ian Jacobs, Robert C. Bast, The CA 125 tumour-associated antigen: a review of the literature Human Reproduction. ,vol. 4, pp. 1- 12 ,(1989) , 10.1093/OXFORDJOURNALS.HUMREP.A136832
S. C. Mok, J. Chao, S. Skates, K.-k. Wong, G. K. Yiu, M. G. Muto, R. S. Berkowitz, D. W. Cramer, Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology Journal of the National Cancer Institute. ,vol. 93, pp. 1458- 1464 ,(2001) , 10.1093/JNCI/93.19.1458
Eleftherios P Diamandis, George M Yousef, Antoninus R Soosaipillai, Peter Bunting, Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma Clinical Biochemistry. ,vol. 33, pp. 579- 583 ,(2000) , 10.1016/S0009-9120(00)00182-X
Christiane Kirchhoff, Inka Habben, Richard Ivell, Nora Krull, A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biology of Reproduction. ,vol. 45, pp. 350- 357 ,(1991) , 10.1095/BIOLREPROD45.2.350
N. Scholler, N. Fu, Y. Yang, Z. Ye, G. E. Goodman, K. E. Hellstrom, I. Hellstrom, SOLUBLE MEMBER(S) OF THE MESOTHELIN/MEGAKARYOCYTE POTENTIATING FACTOR FAMILY ARE DETECTABLE IN SERA FROM PATIENTS WITH OVARIAN CARCINOMA Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 11531- 11536 ,(1999) , 10.1073/PNAS.96.20.11531
K Niwa, M Itoh, T Murase, S Morishita, N Itoh, H Mori, T Tamaya, Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. British Journal of Cancer. ,vol. 70, pp. 1191- 1197 ,(1994) , 10.1038/BJC.1994.472